Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for ...

The “placebo-adjusted” weight loss achieved by Metsera’s drug at 28 weeks of treatment is roughly equal to the 13% achieved by Zebpound at the same stage in a Phase 3 study called Surmount-1, Risinger ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The big banks have started off the new earnings-reporting ...

Today, a brief rundown of news involving I-Mab Biopharma and Taysha Gene Therapies, as well as updates from Sanofi, Adcytherix and Boehringer Ingelheim that you may have missed. MapLight Therapeutics ...

Windlas Biotech Ltd (Windlas) has quietly positioned itself as one of the more interesting mid-cap plays on India’s pharmaceuticals outsourcing wave. The company, headquartered in Dehradun, is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Founded in 2019, Enveda claimed ...

Diagnostic play Nexsen surges 47% on its ASX debut, after a well-supported raising Audeara has entered the Japanese market, we hear FDA drug approvals plunge Shares in our latest ASX biotech entrant ...

ASX 200 closes 0.19% higher after choppy session Strength in mining and energy stocks offset pullback across six sectors, with big four banks among hardest hit In boost for healthcare sector, Biotech ...

Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles ...

Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by ...